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effective blood-flow enhancement therapies are available for these patients. Autologous bone marrow-derived stem cell therapy (ABMSCT) is a modality with an option of promoting new collateral vessels formation through the collaboration of endothelial stem cells (ESCs) and/or endothelial progenitor cells (EPCs) with other hematopoietic cells that act in synergy or complement vasculogenesis by producing angiogenic factors. 1, 2 Recently, 2 types of EPC, early EPC and late EPC also referred to as endothelial outgrowth cells (EOCs) were identified that develop from phenotypically distinct precursors and have different vessel forming C urrently, amputation is the only option for relief of rest pain or gangrene in patients with severe Buerger's disease. Up to now, no No effective blood-flow enhancement therapies are available for patients with severe peripheral arterial disease (SPAD), thus amputation remains the only option for relief of rest pain or gangrene. Autologous bone marrow-derived stem cell therapy (ABMSCT) is an emerging modality to induce angiogenesis from endothelial progenitors. A total of 5 patients with SPAD were treated by ABMSCT using isolated CD34+ cells with characterized phenotype administered by intramuscular injections. The follow-up before and 1, 3, 6, 9, and 12 months after ABMSCT was based on clinical (rest pain, walking distance without pain, nonhealing ulcers, ankle-brachial index [ABI]) and laboratory (angiography, duplex and laser ultrasonography, TcPO 2 ) parameters. Significant improvement of pain and walking distance was observed in all patients.
Nonhealing ulcers disappeared in 3 patients and became smaller and thinner in 1 patient. The average of ABI improved significantly on the treated limb but did not change on the contralateral limb. New collaterals were detected by angiography in 3 patients, but duplex ultrasonography detected improvement in one patient only. Laser ultrasonography showed a mild significant change, TcPO 2 values improved mainly on the foot. Severe adverse events were not observed. We conclude that ABMSCT with isolated CD34+ cells is safe, effective, and results in sustained clinical benefit for patients with SPAD.
Keywords: Buerger's disease; autologous bone marrowderived stem cell therapy; therapeutic angiogenesis; nonhealing ulcer capacities. 3, 4 Thus the efficacy of stem cell therapy in severe peripheral arterial disorder (SPAD) may depend on the source, number, phenotype, and vasculogenic potential of ESC and the composition of the stem cell fractions. 2, 5 Most clinical studies have used autologous mononuclear cells (AMNCs) obtained from peripheral blood after stem cell mobilization [6] [7] [8] [9] [10] [11] or from bone marrow aspirate. [12] [13] [14] [15] [16] [17] [18] Endothelial progenitor cell counts, determined by real-time QRT-PCR and flow cytometry, were found to be higher in the mononuclear cell fraction isolated from the bone marrow than those obtained from peripheral blood after stem cell mobilization. 14 The number of CD133 single positive (CD133+) or CD34 and CD133 double positive (CD34+CD133+) cells of the whole bone marrow-derived AMNC fraction, however, showed similar correlation with the responder status. 18 Surprisingly, recent studies revealed that CD34+CD45−VEGFR2+ cells are able to give rise to EPC, whereas CD34+CD133+ VEGFR2+ cells devoid of vessel forming potential. 4 It was also shown that endothelial colony forming units (CFU-EC) derive from the hematopoietic system and possess myeloid progenitor activity, but proliferating endothelial colony forming cells (ECFC) form vessels in vivo. 19 These results suggested that multiple progenitor cells might be involved in neovascularization and various heterogeneous ESC/EPC sources can be used for therapeutic vasculogenesis. The optimal number and ratio of the functionally relevant cell types, conferring clinical effects, are not yet determined.
In this article, we show for the first time that low numbers of isolated bone marrow-derived CD34+ stem cells that involve CD34+CD133+, CD34+ CD133−, CD34+CD45−, and CD34+CD45+ cells with different vessel forming ability confer vasculogenesis on intramuscular implantation to patients with Buerger's disease or arteriosclerosis obliterans. Our results also revealed that intramuscular implantation of autologous CD34+ cells resulted in complete regression of rest pain, significant increase in pain-free walking distance and the healing of ulcers in all 5 patients treated. As no adverse effects were observed, we conclude that ABMSCT with isolated CD34+ cells is safe and has significant clinical benefit. Furthermore, the therapeutic utility of welldefined cell fractions paves the way for controlled efficacy and dose escalation studies.
Materials and Methods

Study Design
A total of 5 patients with SPAD (4 with Buerger's disease and 1 with arteriosclerosis obliterans) with rest pain and nonhealing ulcer were selected for ABMSCT as approved by national and local ethical committees. We used the term SPAD when vascular surgery operations (angioplasty or bypass) were not possible and conservative therapy was ineffective. The diagnosis and clinical stage was confirmed by digital substraction angiography (DSA), ankle-brachial index (ABI), duplex sonography, laser sonography, and transcutaneous oxygen pressure (TcPO 2 ). Eligibility criteria were as follows: age between 20 and 65 years and severe, surgically not treatable peripheral arterial disease. The possibility of surgical intervention had to be ruled out by an expert vascular surgeon. Patients with diabetes mellitus, retinopathy, malignancies, thrombocytopenia, heart failure (EF < 30%), severe liver or renal failure were excluded. Our goal was to treat the worse limb of all the 5 patients.
Patients
A total of 5 patients (4 White men patients suffered from Buerger's disease and 1 White woman had arteriosclerosis obliterans) were treated between July and September 2006. Age ranged from 25 to 59 years (mean: 43.8 years). The follow-up period was 12 months. To determine limb status, the criteria of both Fontaine and Rutherford were used. The clinical stage of the 5 patients was Fontaine IVa or Rutherford 5.
Clinical Data of Patients Before ABMSCT
Patient 1 was a 48-year-old woman with arteriosclerosis obliterans since 2005. She had rest pain, 20 m walking distance without pain, and 2 nonhealing ulcers on her right leg. In 2006, she had a vascular surgery operation (femoral-popliteal bypass on her right leg) and the same leg was treated by ABMSCT.
Patient 2 was a 59-year-old man with Buerger's disease since 1976. He had rest pain, 50 m walking distance without pain, and 2 large (8 cm 2 ) nonhealing ulcers on both legs. He had sympatectomy on both sides (1982, 1983) . Amputation of the right toe II and left toe I was carried out in 1991, and the amputation of the left toe III was done in 1995. His left lower limb was treated by ABMSCT.
Patient 3 was a 25-year-old man with Buerger's disease since 2001. He had rest pain, <10 m walking distance without pain, and 1 small nonhealing ulcer on his right foot. He had femoral-popliteal bypass surgery on his left leg in 2002 and right sympatectomy in 2006. Stem cell therapy was administered to his right limb.
Patient 4 was a 40-year-old man with Buerger's disease since 1991. He had rest pain, <50 m walking distance without pain, and a large nonhealing ulcer (36 cm 2 ) on his left leg. He had amputations of his left toe I-III and right toe I-II, and left finger III. ABMSCT was given to his left leg.
Patient 5 was a 47-year-old man with Buerger's disease since 2002. He had rest pain, 50 m walking distance without pain, and 1 small nonhealing ulcer on his right toe III. He had amputation of his left finger I. His right lower limb was treated by ABMSCT.
Clinical Measurements
Angiography. GE Advantx DSA device was used to visualize the vessels of both lower extremities before, 1 and 6 months after ABMSCT. Duplex ultrasonography: General Electric Logiq 9, transducer 10L was used before and 1, 3, 6, and 9 months after stem cell therapy. ABI was calculated from the ratio of ankle and brachial systolic pressure. Laser ultrasonography was carried out with a Periflux 5001 instrument (Perimed AB, Jarfalla, Sweden). We evaluated rest flow and the effect of 10-minute local heating (44°C) simultaneously on both lower limbs, first near to the ulcer and then on the medial side of the leg's middle third. We registered continuously the rest flow for 2 minutes at skin temperature, then for 10 minutes heated to 32°C, and finally for 10 minutes at 44°C. Transcutaneous oxygen pressure (TcPO 2 ) was measured with Periflux 5001, on both sides of the foot near to the ulcers, and then on the medial side of the middle calf for 15 minutes. Laser ultrasonography and TcPO 2 measurements were performed before, 1, 6, and 12 months after ABMSCT.
Preparation of Stem Cell Suspension (BM-PC Injection)
Bone marrow (200-300 mL) was aspirated from iliac crest under local anesthesia. CD34+/CD133+/ CD45+ cell counts were determined in aspirated bone marrow, CD34+ cells were isolated by magnetic cell separation (CliniMACSplus Miltenyi, Biotec, Bergisch-Gladbach, Germany), using irondextrane marked anti-CD34 monoclonal antibodies (CliniMACS CD34 Reagent, Miltenyi Biotec) and collected into a 10-mL sample. Quality control of the BM-PC (bone marrow progenitor cell) injection included the following: determination of CD34+/ CD133+/CD45+ cell ratios, viability, and endotoxin content (LAL test). Analysis of stem cell phenotype was performed by flow cytometry according to the ISHAGE protocol. The characteristics of the individual BM-PC suspensions are summarized in Table 1 .
Autologous Stem Cell Therapy
The stem cell suspension contained 81.42% ± 6.8% CD34+ cells, the ratio of CD34+CD133+ endothelial precursors was 40.8 ± 9.0%. Isolated CD34+ cells (0.37-1.14 × 10 5 /kg) were administered by local intramuscular injections (0.5-1.0 mL) into the musculus gastrocnemius of the worse leg of the patient.
Follow-up
The follow-up (before, 1, 3, 6, 9, and 12 months after ABMSCT) was based on the changes of clinical symptoms (rest pain, walking distance without pain, nonhealing ulcers, ABI) and on laboratory (angiography, duplex and laser ultrasonography, TcPO 2 ) measurements.
Statistical Analysis
Data were expressed as mean ± SD and were analyzed by analysis of variance (ANOVA). Difference between means was considered statistically significant at P < .05. Statistical analysis was performed by the Microcal Origin 4.10 software (Microcal Software, Inc; Northampton, MA).
Results
Clinical Follow-up
Application of ABMSCT was well tolerated, did not induce any local side effects such as vascular damage, thrombotic, bleeding, or infectious complications up to 5 days after implantation. Therapeutic benefit was shown by complete regression of rest pain in all 5 patients, and by the significant increase of pain-free walking distance (36 m vs 440 m, P = 2.93 × 10 −7 ; Table 2 ). Twelve months after ABMSCT the ischemic ulcers disappeared in 3 patients (patients 1, 2, and 3), and in another patient (patient 4) the large and deep ulcer became smaller and thinner (36 cm 2 vs 4 cm 2 ). The ulcer did not change in patient 5, where osteomyelitis of the affected toe was diagnosed. The morphological changes of the ischemic ulcers of 3 patients (patients 1, 2, and 4) are shown in Figure 1 .
In all 5 cases we treated the worse limb by stem cell therapy. After 12 months, the state of the contralateral side worsened in all cases. The only patient (patient 2) who had ischemic ulcer on both lower limbs exhibited improvement on the treated side and by 12 months after stem cell therapy the ischemic ulcer disappeared. However, the contralateral limb worsened, and the ulcer became larger and deeper. Rest pain always developed on the leg with ulcer in patients 1, 3, 4, and 5, whereas in patient 2 it disappeared on the treated side only.
Invasive and Noninvasive Measurements
Results of angiography proved a striking increase of visible collateral vessels on the treated side of 3 patients (patients 2, 4, and 5) 6 months after ABM-SCT ( Figure 2 ). Despite healing of their ulcers (Figure 1 ) no vasculogenesis could be shown in the other 2 cases, that is, in patients 1 and 3. The contralateral legs did not change whereas in patient 2 it strongly worsened. Figure 3 shows significant augmentation of ABI values in all cases: 0.41 before treatment, 0.64, 0.76, 0.78, and 0.83 after 3, 6, 9, and 12 months, respectively. ABI values of the contralateral legs did not change significantly. The effect of ABMSCT on microcirculation was monitored by laser ultrasonography and by the measurement of TcPO 2 . We found significant improvement on the calf but not on the foot by laser ultrasonography, whereas TcPO 2 values and the results of duplex ultrasonography did not change significantly 12 months after stem cell therapy as compared to those obtained before stem cell transplantation (Table 3) . These results altogether suggest that the sensitivity of the methods applied (angiography vs duplex ultrasonography, laser Doppler and TcPO 2 ) exhibit different sensitivity to detect the background of clinical improvement.
Safety of the Study
Hematological, liver, and renal laboratory parameters were controlled throughout the treatment. Abnormal results were not observed in any of the cases. C-reactive protein values of the patients did not change as measured 1 week after ABMSCT. Blood creatine kinase increased in 1 patient concomitant with considerable clinical improvement, and remained unchanged in 4 cases. No local inflammation or edema was experienced on the side of ABMSCT. In one of the patients, a mild form of vasculitis was observed, which disappeared after a 5day steroid treatment and did not recur. No severe complication, adverse events were detected during the 12-month follow-up period.
Discussion
Therapeutic vasculogenesis is based on the capability of bone marrow-derived CD34+ hematopoietic stem cells to migrate into ischemic areas and to integrate into newly developing capillaries. 1,2,5 These cells have been shown to include EPC and express receptors for angiogenic factors such as fibroblast growth factor receptor (FGF-R) and vascular endothelial growth factor receptor-2 (VEGF-R2/KDR/Flk1). 12, 13 It was also suggested that other bone marrow progenitors have the capacity to produce angiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and angiopoietin. 12 VEGF directly induces collateral formation, upregulates endothelial nitric oxide synthase (eNOS) expression and the release of nitric oxide, 20 and also enhances blood flow through improving endothelium-dependent vasodilatation. 21 In sum, these results suggest that endothelial dysfunction may be reversible. CD133+ bone marrow-derived cells have been identified as endothelial progenitors 22 and were used in a few clinical trials of SPAD 10 or myocardial infarction. 23 It has also been shown that circulating EPC counts are decreased in patients suffering from advanced peripheral arterial disorders 24 and thus supplementation of these subjects with cell fractions enriched for EPC emerged as a feasible therapy to repair endothelial cell functions and to augment neovascularization of ischemic tissue. CD34+ stem cells can be obtained from peripheral blood following granulocyte colony stimulatory factor (G-CSF) mobilization or directly from the adult bone marrow 12-18 that has been suggested as a promising source of EPC for the treatment of Buerger's disease. 16 A recent study reported on the utility of major histocompatibility complex-matched umbilical mesenchymal stem cells as another option of treating patients with Buerger's disease. 25 In severe arteriosclerosis obliterans the success of stem cell therapy has been reported in 220 patients of 9 independent studies so far. [6] [7] [8] [9] [10] [11] [12] [13] [14] Successful stem cell therapy of patients with severe Buerger's disease has NOTES: ABMSCT = autologous bone marrow-derived stem cell therapy; PU = peak unit; TcPO2 = transcutaneous oxygen pressure; PS velocity = peak systolic velocity; ED velocity = end diastolic velocity. been published for 45 patients of 5 studies. [15] [16] [17] [18] 25 In 2 of these publications, clinical results were reported for both disorders. 14, 18 Results of clinical trials carried out either with bone marrow-derived or peripheral blood-derived stem cells in patients with arteriosclerosis obliterans or Buerger's disease have been proved to be promising, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 25 but no randomized double blind clinical study has been completed so far. Bone marrow-derived mononuclear stem cells were isolated and applied intramuscularly in 7 of these clinical studies. [12] [13] [14] At the same time 7 clinical trials were carried out with mobilized peripheral CD34+ stem cells in PAD. [6] [7] [8] [9] [10] [11] Lenk et al 7 treated 7 patients suffering from PAD 10 with blood mononuclear cells containing 32% CD34+ and 23% CD133+ cells. Sánchez-Guijo et al 10 reported on 3 patients with PAD who were treated with isolated CD133+ stem cells at a dose of 1.2 × 10 6 most comparable with the dose used by us.
In this article, we show the clinical results of 5 patients (4 with severe Buerger's disease and 1 case with severe arteriosclerosis obliterans) who received a single treatment with isolated bone marrowderived CD34+ cells that contained about 40% of CD133+ cells, previously identified as EPC that are able to differentiate toward functional endothelial cells. CD34+CD133+ EPC were recently shown to develop from a minor CD34−CD133+VEGF-R2+ precursor population. 22 The total number of CD34+ cells in the isolated fraction was lower than that applied in the clinical trials performed with nonfractionated mononuclear cells 12, 13 with known EPC counts. 18 The isolated stem cell fraction also contained 20% contaminating CD34− cells. Although the composition and functional activity of these cells was not analyzed, based on a previous study 1 we suggest that despite the lack or the loss of the mature stem cell markers CD34 and CD45, these cells may also contribute to the therapeutic effect.
Therapeutic angiogenesis using AMNC in a recent pilot study (3 patients with Buerger's disease, 4 with arteriosclerosis obliterans) resulted in improved critical limb ischemia in all patients with Buerger's disease but was ineffective in patients with arteriosclerosis obliterans. 18 Our results, although with a limited number of patients, suggest that good clinical results may be achieved in both disorders by using isolated bone marrow-derived CD34+ cells. The study by Durdu et al 15 with AMNC of 28 patients with Buerger's disease demonstrated complete healing of ischemic ulcers in 83% and marked improvement in 17% of cases 6 months after stem cell therapy. The clinical data of almost 50 patients (together with our 4 cases) with advanced Buerger's disease clearly show the efficacy of stem cell therapy and thus identifies this patients group as a primary target of ABMSCT.
A recent study reported on the dose-dependent (1 × 10 3 to 5 × 10 5 /kg) vasculogenic effect of purified CD34+ cells in a nude rat model 26 and suggested the CliniMacs separation technique for human clinical medicine. 27 However, the beneficial effect of stem cell therapy seems to be independent on the homogeneity of the cell fraction (mononuclear cells enriched for stem/progenitor cells or isolated CD34+ and/or CD133+ EPC). Severe adverse events (teratoma formation, accelerated arteriosclerosis) have not been published so far in the context of bone marrow-derived AMNC in patients with PAD. 15, 18 As the optimal therapeutic dose of stem/progenitor cells has not been determined and the contribution of other cell types has not yet been identified, further studies are needed to select the most efficient stem cell source, dose, and mode of administration. The ratio of uncharacterized cells in the CD34+ cell fraction is about 20% compared with the 98% to 99% of highly heterogenous cells in AMNC, with a higher potential of adverse events than that of isolated stem cells. Furthermore, the CliniMacs system offers a reliable technique for the isolation of clinically relevant CD34+ and CD133+ cells that can be used in comparative clinical settings aimed at optimizing neovascularization therapies.
In the present study, we compared the state of the patients' lower limb before and after ABMSCT, and also the state of the treated and the contralateral lower extremities. The ABMSCT significantly improved the clinical state of our patients. The rest pain disappeared in all the 5 cases. The walking distance without pain was less than 50 m before stem cell therapy and 9 months after the treatment it increased to the range of 400 to 500 m (average 36 m vs 440 m). Twelve months after ABMSCT, the ischemic ulcers disappeared in 3 patients, and in another one the large and deep ulcer became smaller and thinner. The clinical improvement started 1 month after ABMSCT, it became more prominent after 3 months, and the best clinical results were observed after 12 months of stem cell therapy. Confirmed by posttrial observations obtained at 15 months (data not shown) the clinical improvement was evaluated as stable and long -lasting.
In all the 5 cases we treated the more painful limb and following ABMSCT each patient stated that his or her transplanted lower limb became better, and all of them asked the treatment of their contralateral lower extremities as soon as possible. When we compared the status of the treated and contralateral limbs instead of the state of the patients' limb before and after ABMSCT, the improvement was even more obvious. In all the 5 cases we noticed improvement on the treated limb only, whereas the contralateral symptoms and ulcer remained unchanged or worsened. Despite the obvious clinical improvement of the treated legs, the results of the instrumental measurements showed only moderate improvement and were highly dependent on the detection method used. ABI values were significantly higher on the treated side, results of angiography proved a striking increase in the number of visible collateral vessels on the treated leg of 3 responding patients. In line with previous data, 5, 24 our results show changes of collateral circulation at later time points (6 months). Duplex ultrasonography showed improvement of circulation only in one case in contrast to the documented new vessel generation in the treated legs of others. This can be explained by the limited sensitivity of duplex ultrasonography to detect new collateral vessels. We were able to measure a mild significant improvement using laser ultrasonography, a method of measuring microcirculation, and the results of TcPO 2 showed a measurable change 12 months after transplantations mainly on the foot. These results strongly support the notion that stem cell therapy confers a local vasculogenic and a long-lasting regenerative effect.
Several important limitations of our study should be noted. First, as it was a pilot trial, only 5 patients were enrolled. Second, because there is no uniformly accepted or validated method for evaluating peripheral microvascular perfusion, it may be argued that the measures used by us are not sensitive or specific enough to detect clinically relevant changes in the disease process. The present phase I-IIa clinical trial, however, showed a significant clinical improvement (relief of rest pain, significant increase in walking distance without pain and in clinical stage of the ischemic ulcers) without any severe adverse events in 5 patients. Thus, ABMSCT performed with enriched CD34+ bone marrowderived stem cells that involve a fraction of CD133+ potential endothelial precursors is safe, effective, and sustained in patients with SPAD. Multicentric, controlled clinical trials are required to confirm these preliminary results and further research is needed to identify the contribution of the distinct cell types and to explore the mechanisms contributing to these effects.
Injection of the cells into the gastrocnemius muscle clearly results in a local effect and in sustained improvement. We suggest that the collaboration of enriched stem and endothelial progenitor cells initiates a cascade of events that involve direct induction of neovascularization, and trophic effects acting on and collaborating with cells of the ischemic tissue. The balance of these mechanisms is very likely changing with time but seem to progress to long-lasting tissue regeneration.
The significance of these type of studies is underscored by the dramatic variation in the prevalence of Buerger's disease among patients with peripheral arterial diseases of various ethnic groups: the percentage of Buerger's disease is 0.5% to 5.6% in Western Europe, 45% to 63% in India, 16% to 66% in Korea and Japan, and ∼80% in Israel among Jews of Ashkenazi ancestry. 28 
